KPI Therapeutics

KPI Therapeutics

The Project

In December of 2015, RLB Holdings became a cornerstone investor and major stockholder in KPI Therapeutics, Inc., a Seattle-based privately held biotechnology company specializing in clinical and commercial advancement of novel drug candidates derived from leading-edge scientific research. In connection with this investment, Ray joined KPI’s Board of Directors.

The Benefit

Through this partnership, RLB provides support for KPI’s clinical and commercial development of their life-changing classes of new drugs which will improve the lives of millions of people suffering from autoimmune diseases and chronic pain.  

Latest NewsVisit Website